<DOC>
	<DOCNO>NCT01208337</DOCNO>
	<brief_summary>This open-label clinical trial evaluate safety efficacy Alemtuzumab ( Campath , Bayer Corp. , Pittsburgh ) child ( 0-17 ) adult ( 18-25 ) receive intestinal transplant . Seventy-five subject receive primary repeat intestine transplantation enrol . Primary endpoint include incidence severity biopsy-proven acute cellular rejection , incidence freedom steroid 5 year , incidence subject steroid-free Tacrolimus whole blood concentration &lt; 10 ng/ml . Secondary endpoint include ) incidence severity opportunistic infection ( CMV EBV ) , post-transplant lymphoproliferative disorder ( PTLD ) , chronic rejection b ) use non-immunosuppressive co-medications , c ) time repopulation lymphocyte subset , ) longitudinal characterization donor-specific alloreactivity mixed lymphocyte response ( MLR ) , identify time decrease level less third-party-specific alloreactivity e ) longitudinal expression ( mRNA ) gene , identify rejection- non-rejection-specific gene f ) characterization whole genome mutation , show difference parent-to-child transmission rejectors non-rejectors . This identify rejection- non-rejection-specific gene bear genetic variant , might impact gene function , complement candidate gene identification effort base SNP transmission .</brief_summary>
	<brief_title>Safety Efficacy Alemtuzumab Pediatric Intestinal Transplantation</brief_title>
	<detailed_description>Intraoperatively , impression Alemtuzumab may predispose mild coagulopathy . Therefore , elect administer steroid , withhold Alemtuzumab operate room small bowel transplant recipient . 1 . Premedication acetaminophen 10 mg/kg orally + diphenhydramine 1 mg/kg intravenously + methylprednisolone 2 mg/kg , intravenously occur 30 minute Alemtuzumab administration . 2 . Steroids 10 mg/kg bolus administer intravenously operate room prior reperfusion allograft follow decreasing amount low-dose steroid post-transplant . Day 1 post-transplant : 5 mg/kg give Day 2 post-transplant : 4 mg/kg give Day 3 post-transplant : 3 mg/kg give Day 4 post-transplant : 2 mg/kg give Day 5 post-transplant : 1 mg/kg give Maintenance steroid taper thereafter switch equivalent amount oral prednisone , soon ileus result oral intake intake possible . By end first month , patient receive 2.5-5 mg/day prednisone . This amount exceed rejection occurs . Long-term prednisone usage may elect patient re-transplanted chronic rejection . 3 . A single dose Alemtuzumab 0.4-0.5 mg/kg give intravenously slowly post-operatively . Total dose exceed 30 mg . Procedures : 1 . Tacrolimus initiate 0.01 mg per kg body weight orally . If biopsy-proven rejection occur , Tacrolimus titrate whole blood concentration : Month 1 : 15-20 ng/ml Months 2-3 : 10-15 ng/ml Month 4-6 : 8-10 ng/ml Months 6-12 : 5-10 ng/ml 2 . This minimization protocol delay 3 month biopsy proven acute cellular rejection occur . At event rejection , Tacrolimus minimization steroid spar discontinue standard immunosuppression institute . For example , rejection occurs , Tacrolimus increase month 1 level 15-20 ng/ml , steroid add regimen . Steroids reduce eliminate within 3 month rejection , tacrolimus minimization resume describe . These level Tacrolimus standard care event rejection . Current immunosuppressive protocol center include rabbit anti-human thymocyte globulin ( rATG ) Tacrolimus monotherapy , Tacrolimus + steroid without induction . 3 . Laboratory test per clinical protocol . The clinical standard care follow perform post-Tx monitoring lab consist complete blood count differential count , serum sodium , potassium , chloride , bicarbonate , BUN , creatinine glucose , liver function test consist Total bilirubin , aspartate alanine transaminase ( ALT ) , aspartate glutamine transaminase ( AST ) , glutamyl galactosyl transaminase ( GGT ) , TAC whole blood concentration . These laboratory test perform least weekly first second month , twice monthly month 3 , monthly thereafter sixth month . The extra 1 11 ml need pharmacodynamic pharmacogenomic study discuss item 5 Table 1 . 4 . Surveillance intestinal allograft biopsy perform per clinical surveillance protocol-twice weekly first month , weekly second month , two-weekly third month , least monthly thereafter end 6th month , least annually thereafter . Surveillance biopsy do blood test exist indicate intestinal allograft dysfunction .</detailed_description>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Age 025 year male female Primary intestine transplantation , repeat intestine transplantation , intestine transplantation set previous simultaneous liver transplantation document noncompliance know hypersensitivity egg protein pregnancy malignancy hepatitis C B define antiHCV antibody positive , antiHepatitis B surface antigen Hepatitis B core antibody positive HBV DNA positive .</criteria>
	<gender>All</gender>
	<minimum_age>4 Months</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Rejection</keyword>
</DOC>